People
Here are five “dreams” that patients are hoping will come to fruition.
Eli Lilly’s senior vice president and chief financial officer Josh Smiley announced plans for the company to spend from $1 billion to $5 billion each quarter this year as it plans to bolster its pipeline.
Collins, a former member of the Innate Immunotherapeutics Board of Directors, was indicted in 2018 and resigned his seat last year.
TCG Lifesciences, a company promoted by New York based Purnendu Chatterjee Group, has announced the induction of Chris Senanayake, as Chief Scientific Officer responsible for delivering highest quality scientific solutions and innovations to its global client base.
Raremark, the leading patient-data platform in rare disease, is pleased to announce additions to its executive team to speed the company’s pursuit of more treatments for rare medical conditions.
Lyfebulb and Helsinn Announce 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award
As the J.P. Morgan Healthcare Conference winds down for 2020, one of the big topics was the general lack of big deals. Still, there were some general trends and for today, some news.
Pharma companies add new members to executive ranks and boards of directors.
The first of the Insys Therapeutics executives found guilty of violating the Racketeer Influenced and Corrupt Organizations Act in May 2019 has been sentenced.
The company, which has secured enormous investments over the past few years, is inching closer to being a commercial company in developing personalized therapies for a wide range of diseases, including cancer.
PRESS RELEASES